BioVersys begins trading on SIX Swiss Exchange
07.02.2025
BioVersys, a Basel-based biotech company focused on combating multidrug-resistant bacteria, is now publicly listed on the SIX Swiss Exchange. Valued at CHF 213 million, the company raised CHF 90 million by offering over 2.2 million shares at CHF 36 each, demonstrating strong investor support for its work.
 |
 |
The funds raised will help BioVersys advance its key products: BV100 for pneumonia and bloodstream infections, and alpibectir for tuberculosis, developed with GSK. These efforts are central to combating antimicrobial resistance. BioVersys' shares will trade under the ticker "BIOV" and are expected to join the Swiss Performance Index by February 10, 2025.
"Today is a major milestone for BioVersys as we take the next step in our growth strategy," says Marc Gitzinger, founder and CEO of BioVersys. “We are truly encouraged by the positive demand and strong investor interest we have received over the past weeks. This support enables us to move full speed ahead with BV100 into the Phase 3 program, advance alpibectir into additional Phase 2 trials in collaboration with GSK and further progress our early-stage pipeline. I want to extend my sincere gratitude to everyone who has contributed to this achievement - our dedicated employees, partners, shareholders, and all stakeholders who share our vision. Together, we remain fully committed to bringing urgently needed antibiotics to severely ill patients worldwide.”
It all started in 2007 when ETH student Marc Gitzinger participated with his startup idea in 2007 in Venturelab's Venture Challenge semester course at ETH Zurich to learn how to start a biotech company. With the support of Venture Kick in 2008 he received CHF 130’000 to incorporate the BioVersys AG. In the same year, Gitzinger participated in the Venture Leaders business development roadshow in Boston to take the first step to go global.
"We at Venturelab are very happy for Marc and the entire BioVersys team,” says Stefan Steiner, Co-Managing Director at Venturelab. “It's incredible to see how far they've come since Marc's start 2007 at a Venture Challenge course. We've been proud to support them every step of the way, right up to this remarkable IPO milestone."
BioVersys was also awarded several years with the TOP 100 Swiss Startup label and participated in 2022 in the first SIX IPO Academy to prepare and equip TOP 100 scaleups for a potential IPO on the Swiss Stock Exchange.
Steiner looks forward to more: "BioVersys' IPO on the SIX Swiss Exchange sets a positive example. More exits and IPOs will drive the Swiss startup ecosystem forward. Hopefully, this is just the beginning after a restrained 2024."
"Today is a major milestone for BioVersys as we take the next step in our growth strategy," says Marc Gitzinger, founder and CEO of BioVersys. “We are truly encouraged by the positive demand and strong investor interest we have received over the past weeks. This support enables us to move full speed ahead with BV100 into the Phase 3 program, advance alpibectir into additional Phase 2 trials in collaboration with GSK and further progress our early-stage pipeline. I want to extend my sincere gratitude to everyone who has contributed to this achievement - our dedicated employees, partners, shareholders, and all stakeholders who share our vision. Together, we remain fully committed to bringing urgently needed antibiotics to severely ill patients worldwide.”
It all started in 2007 when ETH student Marc Gitzinger participated with his startup idea in 2007 in Venturelab's Venture Challenge semester course at ETH Zurich to learn how to start a biotech company. With the support of Venture Kick in 2008 he received CHF 130’000 to incorporate the BioVersys AG. In the same year, Gitzinger participated in the Venture Leaders business development roadshow in Boston to take the first step to go global.
"We at Venturelab are very happy for Marc and the entire BioVersys team,” says Stefan Steiner, Co-Managing Director at Venturelab. “It's incredible to see how far they've come since Marc's start 2007 at a Venture Challenge course. We've been proud to support them every step of the way, right up to this remarkable IPO milestone."
BioVersys was also awarded several years with the TOP 100 Swiss Startup label and participated in 2022 in the first SIX IPO Academy to prepare and equip TOP 100 scaleups for a potential IPO on the Swiss Stock Exchange.
Steiner looks forward to more: "BioVersys' IPO on the SIX Swiss Exchange sets a positive example. More exits and IPOs will drive the Swiss startup ecosystem forward. Hopefully, this is just the beginning after a restrained 2024."
BioVersys (@Bioversys) has officially gone public on the @sixgroup Swiss Exchange! With a successful CHF 90 million IPO, this biotech pioneer is set to accelerate the fight against antimicrobial resistance, a major global health challenge. This milestone proves that Swiss… pic.twitter.com/OikpwYAmzh
— Venturelab (@venturelab_ch) February 7, 2025
Additional Links
- BioVersys' profile on Venture Kick
- BioVersys sets IPO price at CHF 36.00 per share ahead of SIX Swiss Exchange debut
- Swiss biotech firm BioVersys plans IPO at SIX Swiss Exchange in first quarter 2025
- BioVersys strengthens tuberculosis drug development with expanded GSK collaboration and CHF 12.3 million Series C boost